CastaÃ±Ã³n E, Rolfo C, ViÃ±al D, LÃ³pez I, Fusco J, Santisteban M, et al. Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis. J Transl Med. 2015;13:257 pubmed publisher
..81). Overall, liver metastases at onset negatively impact OS of NSCLC patients. EGFR TKIs however, may reverse the effects of an initial negative prognosis of liver metastasis in first-line treatment of EGFR mutated NSCLC patients. ..
Martin Romano P, Jurado M, Idoate M, Arbea L, Hernandez Lizoain J, Cano D, et al. Durable complete remission with aromatase inhibitor therapy in a patient with metastatic uterine carcinosarcoma with poor performance status and coagulation disorders: a case report. J Med Case Rep. 2017;11:115 pubmed publisher
..Systemic therapies such as hormone inhibitors should be taken into consideration and deserve further clinical research in the era of precision medicine. ..